File Download
 
Links for fulltext
(May Require Subscription)
  • Find via
 
Supplementary

Conference Paper: Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients
  • Basic View
  • Metadata View
  • XML View
TitleTelbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients
 
AuthorsDiBisceglie A, A
Lai, CL
Gane, E
Chen, YC
Thongsawat, S
Wang, YM
Chen, YG
Heathcote, EJ
Zeuzem, S
Rasenack, J
Bzowej, N
Han, SH
Naoumov, N
Hwang, SG
Lim, SG
Chao, GC
Fielman, BA
Brown, NA
Study Group The GLOBE,
 
Issue Date2006
 
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
 
CitationHepatology, v. 44 n. Suppl 1, p. 231A [How to Cite?]
 
ISSN0270-9139
2013 Impact Factor: 11.190
 
DC FieldValue
dc.contributor.authorDiBisceglie A, A
 
dc.contributor.authorLai, CL
 
dc.contributor.authorGane, E
 
dc.contributor.authorChen, YC
 
dc.contributor.authorThongsawat, S
 
dc.contributor.authorWang, YM
 
dc.contributor.authorChen, YG
 
dc.contributor.authorHeathcote, EJ
 
dc.contributor.authorZeuzem, S
 
dc.contributor.authorRasenack, J
 
dc.contributor.authorBzowej, N
 
dc.contributor.authorHan, SH
 
dc.contributor.authorNaoumov, N
 
dc.contributor.authorHwang, SG
 
dc.contributor.authorLim, SG
 
dc.contributor.authorChao, GC
 
dc.contributor.authorFielman, BA
 
dc.contributor.authorBrown, NA
 
dc.contributor.authorStudy Group The GLOBE,
 
dc.date.accessioned2010-09-25T20:12:49Z
 
dc.date.available2010-09-25T20:12:49Z
 
dc.date.issued2006
 
dc.identifier.citationHepatology, v. 44 n. Suppl 1, p. 231A [How to Cite?]
 
dc.identifier.hkuros133900
 
dc.identifier.issn0270-9139
2013 Impact Factor: 11.190
 
dc.identifier.issueSuppl 1
 
dc.identifier.openurl
 
dc.identifier.spage231
 
dc.identifier.urihttp://hdl.handle.net/10722/101994
 
dc.identifier.volume, v. 44 n. Suppl 1
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
 
dc.relation.ispartofHepatology
 
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.
 
dc.titleTelbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>DiBisceglie A, A</contributor.author>
<contributor.author>Lai, CL</contributor.author>
<contributor.author>Gane, E</contributor.author>
<contributor.author>Chen, YC</contributor.author>
<contributor.author>Thongsawat, S</contributor.author>
<contributor.author>Wang, YM</contributor.author>
<contributor.author>Chen, YG</contributor.author>
<contributor.author>Heathcote, EJ</contributor.author>
<contributor.author>Zeuzem, S</contributor.author>
<contributor.author>Rasenack, J</contributor.author>
<contributor.author>Bzowej, N</contributor.author>
<contributor.author>Han, SH</contributor.author>
<contributor.author>Naoumov, N</contributor.author>
<contributor.author>Hwang, SG</contributor.author>
<contributor.author>Lim, SG</contributor.author>
<contributor.author>Chao, GC</contributor.author>
<contributor.author>Fielman, BA</contributor.author>
<contributor.author>Brown, NA</contributor.author>
<contributor.author>Study Group The GLOBE,</contributor.author>
<date.accessioned>2010-09-25T20:12:49Z</date.accessioned>
<date.available>2010-09-25T20:12:49Z</date.available>
<date.issued>2006</date.issued>
<identifier.citation>Hepatology, v. 44 n. Suppl 1, p. 231A</identifier.citation>
<identifier.issn>0270-9139</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/101994</identifier.uri>
<language>eng</language>
<publisher>John Wiley &amp; Sons, Inc. The Journal&apos;s web site is located at http://www.hepatology.org/</publisher>
<relation.ispartof>Hepatology</relation.ispartof>
<rights>Hepatology. Copyright &#169; John Wiley &amp; Sons, Inc.</rights>
<title>Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients</title>
<type>Conference_Paper</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0270-9139&amp;volume=44&amp;issue=Suppl 1&amp;spage=231A&amp;epage=&amp;date=2006&amp;atitle=Telbivudine+Globe+Trial:+Maximal+Early+HBV+Suppression+is+Predictive+of+Optimal+Two-year+Efficacy+in+Nucleoside-treated+Hepatitis+B+Patients</identifier.openurl>
<identifier.hkuros>133900</identifier.hkuros>
<identifier.volume>, v. 44 n. Suppl 1</identifier.volume>
<identifier.issue>Suppl 1</identifier.issue>
<identifier.spage>231</identifier.spage>
</item>